Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average) (2020 - 2025)

Ultragenyx Pharmaceutical has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $98.6 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 8.95% to $98.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.6 million through Dec 2025, up 8.95% year-over-year, with the annual reading at $98.6 million for FY2025, 8.95% up from the prior year.
  • Shares Outstanding (Diluted Average) was $98.6 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $99.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $99.8 million in Q3 2025 and troughed at $67.5 million in Q3 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $72.2 million (2023), against an average of $80.1 million.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 1.23% in 2023 and then rose 25.11% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $67.8 million in 2021, then increased by 3.13% to $69.9 million in 2022, then grew by 5.13% to $73.5 million in 2023, then grew by 23.13% to $90.5 million in 2024, then grew by 8.95% to $98.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Shares Outstanding (Diluted Average) are $98.6 million (Q4 2025), $99.8 million (Q3 2025), and $97.4 million (Q2 2025).